Lilly to buy Adverum Biotechnologies
The acquisition strengthens Lilly’s genetic medicine pipeline and expands its footprint in ophthalmology.
The acquisition strengthens Lilly’s genetic medicine pipeline and expands its footprint in ophthalmology.
Lilly’s oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
Eli Lilly and Company enhances digital healthcare offerings to address delays in diagnosis and treatment.